CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 475 enrolled
Drug / intervention
PriorixTM +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00751348
NCT00751348Phase 3Completed
CompareCT.gov

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

GlaxoSmithKline·interventional·Posted Sep 11, 2008·Updated Jun 8, 2018

In Brief

A Phase 3 clinical trial evaluating PriorixTM, VarilrixTM, and 1 other intervention for Measles and 3 related conditions. Completed, enrolled 475 participants across 13 sites.

Detailed Summary

This Phase 3b study is being conducted for the purpose of registration of the GSK208136 vaccine in Korea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMeasles, Varicella, Mumps, Rubella
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 11, 2008
Enrollment StartOct 1, 2008
Primary CompletionMay 27, 2010
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 17.8 years ago

Interventions

PriorixTMbiological

Subcutaneous administration in left upper arm

VarilrixTMbiological

Subcutaneous administration in right upper arm

Priorix-Tetra®biological

Subcutaneous injection in left upper arm